|
FY2025
12 months to Dec 27, 2025
|
FY2024
12 months to Dec 28, 2024
|
FY2023
12 months to Dec 30, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 25, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Service | |||||
| Product | |||||
| Total revenue | |||||
| Costs and expenses | |||||
| Cost of revenue (excluding amortization of intangible assets) | |||||
| Service | |||||
| Product | |||||
| Selling, general and administrative | |||||
| Amortization of intangible assets | |||||
| Intangible asset impairment | |||||
| Goodwill impairment | |||||
| Operating income | |||||
| Other income (expense) | |||||
| Interest income | |||||
| Interest expense | |||||
| Other income (expense), net | |||||
| Income (loss) before income taxes | |||||
| Provision for income taxes | |||||
| Net income (loss) | |||||
| Less: Net income attributable to noncontrolling interests | |||||
| Net income (loss) attributable to Charles River Laboratories International, Inc. | |||||
| Less: Incremental dividends attributed to noncontrolling interest holders | |||||
| Net income (loss) available to Charles River Laboratories International, Inc. common shareholders | |||||
| Earnings (loss) per common share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average number of common shares outstanding | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...
